Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (6)

« Back to Publications

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib.

Bye AP. et al, (2023), Haematologica, 108, 1429 - 1435

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.

Wilson MR. et al, (2022), Blood, 139, 2499 - 2511

Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England.

Higgins H. et al, (2022), Res Pract Thromb Haemost, 6

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.

Djebbari F. et al, (2022), PLoS One, 17

Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients.

Rampotas A. et al, (2021), Eur J Haematol, 106, 563 - 573

Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

Lees C. et al, (2019), Br J Haematol, 185, 25 - 41